Holen Sie sich die Stockscreener-App
13.00
1.33%
0.17
Handel nachbörslich:
12.80
-0.20
-1.54%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$12.83
Offen:
$12.78
24-Stunden-Volumen:
8.69M
Relative Volume:
1.19
Marktkapitalisierung:
$15.37B
Einnahmen:
$15.24B
Nettoeinkommen (Verlust:
$-646.50M
KGV:
8.4967
EPS:
1.53
Netto-Cashflow:
$1.88B
1W Leistung:
-0.69%
1M Leistung:
+10.54%
6M Leistung:
+18.40%
1J Leistung:
+37.57%
1-Tages-Spanne:
$12.68
$13.06
1-Wochen-Bereich:
$12.53
$13.17
52-Wochen-Spanne:
$9.08
$13.62
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Safecor Health Announces Acquisition of Viatris' U.S. Unit-Dose Packaging Business - Kilgore News Herald
VSCP-backed Safecor Health picks up Viatris Inc’s US unit-dose packaging business - PE Hub
Influenza Vaccines Industry May See a Big Move | BIKEN, Viatris, Sinovac Biotech - openPR
Chris Davis's Strategic Acquisition of Viatris Inc Shares - GuruFocus.com
Viatris's SWOT analysis: generic drug maker's stock faces growth hurdles - Investing.com
Viatris Inc's chief accounting officer sells $346,686 in stock - Investing.com India
Viatris Inc's chief accounting officer sells $346,686 in stock By Investing.com - Investing.com Australia
YieldBoost VTRS To 8.9% Using Options - Nasdaq
Bargain Priced Viatris Reports Strong Q3 Earnings Results (NASDAQ:VTRS) - Seeking Alpha
Viatris Inc. (NASDAQ:VTRS) Q3 2024 Earnings Call Transcript - MSN
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus.com
Viatris: Q3 Earnings Snapshot - AOL
Viatris reports 71% decline in Q3 2024 net income to $95m - World Pharmaceutical Frontiers
Earnings call: Viatris reports robust Q3 with revenue growth and debt reduction - Investing.com India
Viatris Inc. Reports Strong Q3 2024 Performance - TipRanks
Viatris Outshines Wall Street With Unexpected Profit Gains - Finimize
Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance - MSN
Viatris Reports Third Quarter Financial Results for 2024 - citybiz
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown - Benzinga
Viatris Inc (VTRS) Q3 2024 Earnings: Revenue Hits $3.8 Billion, EPS Falls Short at $0.08 - GuruFocus.com
Viatris stock jumps after Q3 beat (VTRS:NASDAQ) - Seeking Alpha
Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xanax maker Viatris beats quarterly estimates on demand for new generic drugs - Reuters
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Viatris Q3 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Viatris Inc. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Viatris to Report Q3 Earnings: What's in the Cards? - MSN
Viatris Q3 Earnings Preview: Focus on upcoming product launches and EBITDA growth - Seeking Alpha
Are Wall Street Analysts Predicting Viatris Stock Will Climb Or Sink? - Barchart
Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink? - MSN
Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor Type - GlobeNewswire Inc.
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings? - Yahoo Finance
Viatris Announces Third Quarter 2024 Dividend - BioSpace
Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021 - BioSpace
Where are the Opportunities in (VTRS) - Stock Traders Daily
Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Covestro, American Eagle, Howmet and Viatris all make Forbes list of Top Companies for Women - The Business Journals
Viatris Named to Forbes' World's Top Companies for Women 2024 List - Quantisnow
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - StreetInsider.com
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):